Schering Hunting Biotech Deals To Complement Specialty Portfolio
Executive Summary
Schering-Plough is focusing its in-licensing activities on specialty biotechnology products, CEO Fred Hassan told analysts during the company's business review in New York City Nov. 18
You may also be interested in...
Genzyme To Expand Presence In Oncology Through Licensing Deals In 2004
Genzyme is looking to expand its presence in oncology through in-licensing activities in 2004
Genzyme To Expand Presence In Oncology Through Licensing Deals In 2004
Genzyme is looking to expand its presence in oncology through in-licensing activities in 2004
Merger Outlook For 2004: Pfizer Fortunes Key To More M&A, Analysts Say
A demonstration by Pfizer of renewed vigor following the acquisition of Pharmacia could kick off another round of merger & acquisition activity in 2004, securities analysts predict